1. FLT3 Inhibitors in AML

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Mutational Complexity of AML

4. FLT3 Mutations in AML

5. FLT3 Inhibitors in Clinical Development

6. 7+3/Midostaurin vs 7+3/Placebo Phase 3 CALGB 10603 (RATIFY)[a]

7. OS CALGB 10603 (RATIFY), Phase 3

8. OS After AlloHSCT in CR1 CALGB 10603 (RATIFY), Phase 3

9. DFS During Maintenance CALGB 10603 (RATIFY), Phase 3

10. DFS After Maintenance CALGB 10603 (RATIFY), Phase 3

11. Gilteritinib in FLT3-Mutated R/R AML CHRYSALIS, Phase 1/2

12. ADMIRAL TRIAL – Gilteritinib in R/R AML

13. Quizartinib in FLT3-ITD+ R/R AML Randomized Phase 2 Study

14. QuANTUM-R Study Design

15. QuANTUM-R Primary Endpoint Overall Survival by Kaplan-Meier Method

16. QuANTUM-R Best Response

17. Comparison of Primary and Prespecified Sensitivity Analyses of OS in QuANTUM-R

18. Crenolanib in FLT3-Mutated R/R AML Phase 2 Results

19. Dose-Ranging Study of Gilteritinib in ND AML Updated Results at ASH 2018

20. Quizartinib With Standard Chemotherapy in ND AML Phase 1b Study

21. Crenolanib With Standard AML Therapy Phase Ib Study

22. Sorafenib Plus Azacytidine FLT3-ITD+ R/R AML, Phase 2 Study

23. Sorafenib Plus Azacytidine Newly Diagnosed FLT3-ITD+ AML

24. Quizartinib Plus Azacytidine or LDAC Phase 1/2 Trial

25. FLT3 Inhibitors as Maintenance Post-AlloSCT

26. Applying Recent Data to the Clinic

27. Practical Issues in FLT3 Mutation Testing Expert Perspectives

28. When Can You Give FLT3 Inhibitors?

29. FLT3 Inhibitors as a Bridge to Transplant?

30. Conclusions

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)